Medical Developments International Limited

Equities

MVP

AU000000MVP2

Pharmaceuticals

Market Closed - Australian S.E. 02:10:52 2024-04-24 am EDT 5-day change 1st Jan Change
0.56 AUD +1.82% Intraday chart for Medical Developments International Limited +1.82% -26.32%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : Medical Developments International Limited, H1 2024 Earnings Call, Feb 29, 2024
Medical Developments International Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI
Medical Developments International Limited(ASX:MVP) dropped from S&P/ASX Emerging Companies Index CI
Transcript : Medical Developments International Limited, 2023 Earnings Call, Aug 31, 2023
Medical Developments International Limited Appoints Russell Basser to the Board Effective 1 September 2023 CI
Medical Developments International Limited Reports Earnings Results for the Full Year Ended June 30, 2023 CI
Medical Developments International Limited Announces Resignation of David Williams from Board CI
Medical Developments International Searches for Partner to Commercialize Pain Relief Product in the US MT
Medical Developments International Limited(ASX:MVP) dropped from S&P/ASX All Ordinaries Index CI
Transcript : Medical Developments International Limited, H1 2023 Earnings Call, Feb 24, 2023
Medical Developments International Limited Reports Earnings Results for the Half Year Ended December 31, 2022 CI
Medical Developments Stops Clinical Trial Preparation for Penthrox in China; Shares Rise 6% MT
Medical Developments International Limited Discontinues China Clinical Trials CI
Medical Developments International Limited Provides Revenue Guidance for the Year 2023 CI
Medical Developments International Limited Announces Resignation of Max Johnston as Director, Effective 27 October 2022 CI
Medical Developments International Limited(ASX:MVP) dropped from S&P Global BMI Index CI
Medical Developments International Limited Reports Earnings Results for the Full Year Ended June 30, 2022 CI
Medical Developments International Limited Reports Earnings Results for the Full Year Ended June 30, 2022 CI
Medical Developments International Sees Negative FY22 EBITDA, Launches Capital Hike MT
Medical Developments International Limited Provides Earnings Guidance for the Fiscal Year 2022 and Revenue Guidance for the Fiscal Year 2023 CI
Medical Developments International Limited Appoints Tara Eaton as General Counsel and Company Secretary, Effective August 8, 2022 CI
Medical Developments International Signs New Penthrox Licensing Agreement in Canada with New Partner Endo Ventures Limited CI
Medical Developments International Limited Announces Chief Financial Changes CI
Medical Developments International Limited Announces Board Changes CI
Australian Shares Post Modest Gains as GDP Rebounds in Q4 2021 MT
Chart Medical Developments International Limited
More charts
Medical Developments International Limited is an Australia-based company that delivers emergency medical solutions dedicated to improving patient outcomes in both domestic and international markets. The Company operates in two segments: Pain Management and Respiratory. The Pain Management segment is engaged in the supply of analgesia for acute and procedural pain. The Company manufactures inhaled analgesic, Penthrox (the Green Whistle), at manufacturing facilities at Scoresby and Springvale in Victoria, Australia. Penthrox is sold into domestic and international markets through distribution partnerships and direct in-market capability. The Respiratory segment is a supplier of respiratory products including asthma and chronic obstructive pulmonary disease (COPD) space chambers, peak flow meters, portable nebulizers and silicone face masks. Respiratory supplies into Australia, the United States of America, Europe, and Asia through partnerships with distributors.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings
  1. Stock Market
  2. Equities
  3. MVP Stock
  4. News Medical Developments International Limited
  5. Medical Developments Secures US FDA Approval for Phase 3 Pain Medication Trial; Shares Surge 30%